ArticlePloS one2025
Improving segmentation precision in prostate cancer adaptive radiation therapy with a patient-specific network.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence in prostate cancer: navigating the new frontier of precision uro-oncology.American journal of clinical and experimental urology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adaptive radiotherapy (ART) enhances prostate cancer treatment by accounting for daily anatomical variations, but clinical implementation remains limited due to the need for accurate and efficient auto segmentation; manual corrections after automated contouring often hinder workflow efficiency. To address this, we propose a patient-specific network (PSN) approach for clinical target volume (CTV) segmentation using cone-beam computed tomography (CBCT). This retrospective study included 26 prostate cancer patients treated with CBCT-guided online ART using the Ethos therapy system, comprising 119 retrospectively exported fractions. The PSN framework uses a two-stage strategy: initial pre-training followed by patient-specific fine-tuning via PSNadaptive or PSNsequence, implemented with the Swin UNETR architecture. This approach is distinct from static personalization methods as it continuously adapts to daily anatomical changes. Segmentation performance was compared against deformable registration and generalized deep learning models using the Dice similarity coefficient (DSC), 95th percentile Hausdorff distance (HD), and mean surface distance (MSD). PSN significantly improved segmentation performance, with PSNadaptive achieving a DSC of 0.978 ± 0.005, HD of 1.681 ± 0.743 mm, and MSD of 0.510 ± 0.035 mm by the fifth fraction, with accuracy improving across sequential fractions. Visual assessments confirmed high agreement with physician contours, especially in anatomically complex regions. These findings support the PSN framework as a clinically feasible and accurate solution for patient-specific segmentation in prostate ART, potentially reducing the need for manual editing, streamlining workflow efficiency, and enhancing the precision of adaptive treatment delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.